Clinical trial · no report yet · Phase 3
NCT06377852
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- NCT06377852 ↗
- Recruiting
- American Society of Clinical Oncology
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib 125mg; Ribociclib 600mg; Ribociclib; Palbociclib
- Arms
- Arm 1: Indicated Dose · Experimental
- Arm 2: Titrated Dose · Experimental
- Enrollment
- 500 (estimated)
- Primary outcomes
- Time to Treatment Discontinuation (TTD)
- Sponsor
- American Society of Clinical Oncology with Patient-Centered Outcomes Research Institute
- Start
- Oct 29, 2024
- Primary completion
- Aug 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06377852 · updated Oct 6, 2026